IL-23 dominance in psoriasis settles in
IL-23 inhibitors have become the default systemic option for moderate-to-severe psoriasis, leaving IL-17 and TNF in second-line slots.
Psoriasis sequencing has settled. IL-23 inhibitors are the default systemic biologic for most moderate-to-severe patients, with IL-17 and TNF retained for specific clinical scenarios. The conversation has moved on from comparative efficacy to durability and dose-spacing.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is lupus nephritis?
- SnapshotLupus nephritis therapy reference (2026)
- ExplainedWhat is Sjogren disease?
- ExplainedWhat is ANCA-associated vasculitis?
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.